| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Solid TumorsGenitourinary Cancers |
1 Department of Nuclear Medicine; 2 Department of Radiology, University of Bonn, Bonn, Germany; 3 Medizin Center Bonn, Bonn, Germany
81
Objectives: 18F-fluorocholine PET has been recently introduced for imaging of prostate cancer disease but yielded inconclusive results regarding its diagnostic value. Aim of the present study was to compare the results of 18F-fluoromethylcholine PET/CT (FMCH) to MRI for primary diagnosis or restaging of prostate cancer disease.
Methods: 10 patients (age: 62.1±6.2 years) with suspicion of primary (n=8) or recurrent (n=2) prostate cancer were included in this analysis. In all patients PSA-levels were elevated or increasing (PSA: 10.0±7.3 ng/ml; range: 1.3-21.0). After CT acquisition, PET acquisition (CTI PET/CT reveal XVI) of the pelvis was started approximately 15min after i.v.-inj. of 199.4±29.0 MBq 18F-fluoromethylcholine. PET, CT, and PET/CT slices were generated. MRI was conducted at a 1.5 Tesla whole body system (Symphony, Siemens Medical Systems) using a body array and an endorectal coil. FMCH and MRI data were independently evaluated by two experienced physicians blinded to all patients characteristics and correlated regarding findings within the prostate bed.
Results: MRI revealed positive findings within the prostate bed in all included patients. FMCH correlated positively with these results in 9 patients (90%) but in 1 in whom FMCH accumulation could not be surely differentiated from bladder activity. FMCH and MRI were even positive in a patient with a slightly increased PSA-level of 1.3 ng/ml and suspicion of local recurrence of prostate cancer.
Conclusions: Our initial results in patients with elevated or increasing PSA-levels showed FMCH as a reliable diagnostic tool for the detection of primary or recurrent prostate cancer disease.
| ||||||||||||||||||||||||||||||||||||||
